Furthermore, in this setting it is conceivable that a targeted approach for preventing LITAF activity could mitigate NAFLD-related liver damage by reducing both hepatic and systemic IL-1β production/release. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.